Gilead Sciences, Inc. (NASDAQ:GILD) is a leading biopharmaceutical company renowned for its groundbreaking treatments, especially in the HIV sector. The company recently garnered attention following Morgan Stanley's decision to upgrade its stock rating to "Overweight" on October 31, 2025. Concurrently, GILD's stock price was noted at $120.83, with Morgan Stanley elevating its price target from $143 to $147.
Gilead's notable accomplishments include securing the 2025 Prix Galien USA Award for Best Pharmaceutical Product with Yeztugo® (lenacapavir). This accolade underscores the company's dedication to enhancing HIV treatment options. Yeztugo® represents a significant advancement as a twice-yearly injectable HIV-1 capsid inhibitor, serving as an effective pre-exposure prophylaxis (PrEP) for individuals at risk of HIV-1 infection.
The stock for GILD is currently valued at $121.08, reflecting an approximate increase of 2.23%. Today, the stock has ascended by $2.64, trading between a low of $114.02 and a high of $121.91. Over the past year, GILD has experienced a peak of $124.61 and a trough of $86.08, showcasing notable stock price volatility.
With a market capitalization of roughly $150.24 billion, Gilead solidifies its significant stature within the biopharmaceutical sector. The trading volume for GILD today stands at 3,555,932 shares, reflecting robust investor engagement. The company's recent successes, coupled with Morgan Stanley's optimistic forecast, are likely to bolster ongoing investor confidence in GILD.
